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Hydroxyurea (HU) is a crucial therapy for children with sickle cell anemia, but its off-label use is
a barrier to widespread acceptance. We found HU exposure is not significantly altered by liquid vs
capsule formulation, and weight-based dosing schemes provide consistent exposure. HU is
recommended for all children starting as young as 9 months of age with sickle cell anemia (SCA;
HbSS and HbSβspan0thalassemia); however; a paucity of pediatric data exists regarding the
pharmacokinetics (PK) or the exposure-response relationship of HU. This trial aimed to
characterize the PK of HU in children and to evaluate and compare the bioavailability of a liquid
vs capsule formulation. This multicenter; prospective; open-label trial enrolled 39 children with
SCA who provided 682 plasma samples for PK analysis following administration of HU.
Noncompartmental and population PK models are described. We report that liquid and capsule
formulations of HU are bioequivalent; weight-based dosing schemes provide consistent drug
exposure; and age-based dosing schemes are unnecessary. These data support the use of liquid HU
in children unable to swallow capsules and in those whose weight precludes the use of fixed
capsule formulations. Taken with existing safety and efficacy literature; these findings should
encourage the use of HU across the spectrum of age and weight in children with SCA; and they
should facilitate the expanded use of HU as recommended in the National Heart; Lung; and Blood
Institute guidelines for individuals with SCA.

Keywords
bioequivalent; hydroxyurea. children; sickle cell anemia
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Sickle cell anemia (SCA; HbSS and HbSβ0thalassemia) is a chronic, debilitating, and costly
1
disease affecting an estimated 100,000 individuals in the United States. Hydroxyurea (HU),
a ribonucleotide reductase inhibitor, is a potent fetal hemoglobin inducer and antisickling
agent. In 1998, HU received approval by the US Food and Drug Administration (FDA) for
adults with SCA, largely based on data generated from the Multicenter Study of
Hydroxyurea in Patients with Sickle Cell Anemia (MSH) trial (NCT00000586). The MSH
trial showed that HU was safe and significantly decreases the incidence of pain, acute chest
2
syndrome, hospitalization, and transfusion in adults with severe SCA.
1

An estimated 36,000 children (<19 years old) suffer from SCA in the United States. Since
its approval for adult usage, HU has been prescribed off-label for children with SCA to
ameliorate their disease, and the laboratory and clinical benefits in children parallel those
J Clin Pharmacol. Author manuscript; available in PMC 2017 March 01.

Estepp et al.

Page 3

Author Manuscript

seen in adults with reductions in pain, acute chest syndrome, hospitalizations, and
3 9
transfusion requirements. – In September 2014, an expert panel selected by the National
Heart, Lung, and Blood Institute (NHLBI) released evidence-based management guidelines
for sickle cell disease. Included in these guidelines was a “strong recommendation” for
children ≥9 to ≤42 months of age and a “moderate recommendation” for children >42
10
months of age to be offered HU therapy to reduce complications related to SCA.

Author Manuscript

Despite supporting data and recommendations, pediatric use continues to be off-label. FDA
approval requires additional pharmacokinetic (PK) information to include a pediatric
indication on the label for HU and approve it for pediatric use. Although efficacy and
8 9 11 12
toxicity profiles of HU in children with SCA have been favorable, , , , limited data exist
regarding the PK or exposure-response relationship. The FDA offered a written request
under the Best Pharmaceuticals for Children Act (BPCA) to specifically address this
knowledge gap and highlighted the need for PK data to compare liquid to capsule
formulations.
In response to this written request, the “Pharmacokinetics and Bioavailability of a Liquid
Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia” trial
(NCT01506544) was designed to characterize the disposition of a liquid HU formulation in
a cohort of toddlers (≥2 to ≤5 years). This study had two hypotheses: (1) the PK in toddlers
administered a liquid formulation would not differ significantly from that observed in older
children; and (2) the PK profile of the liquid formulation would not differ significantly from
the PK profile of a proprietary capsule formulation.

Methods
Author Manuscript

Study Population

Author Manuscript

Study Design

Following approval from each local center’s institutional review board, children ≥2 to ≤17
years of age were recruited from 7 medical centers in the United States. Eligible participants
had either HbSS or HbSβ0 thalassemia. The inclusion criteria included being in a “well”
state (ie, no acute SCA manifestations or other acute illness), weight of ≥10 kg, body mass
index (BMI) ≥5th and ≤95th percentiles, and normal hepatic, renal, and gastrointestinal
function. Children were ineligible if they had a malignancy, had received a recent blood
transfusion, or had cytopenia noted on screening laboratory assessment. Additionally,
children were excluded for concomitant medication usage that could potentially affect the
analysis (Tables S1 and S2). Of note, 90% (n = 35/39) of children were actively being
treated with HU.

This was a prospective, open-label, trial composed of 2 arms that assessed the PK
parameters of HU administered under direct supervision. Participants were allowed only
clear liquids from 6 hours to 1 hour prior to HU administration, and they abstained from
food or drink 1 hour before and 1 hour following drug administration. A regular ageappropriate diet was resumed 2 hours after dosing. In arm 1, toddlers (≥2 to ≤5 years) (n =
17) received a single dose of a standardized liquid formulation of HU (100 mg/mL). In arm
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2, children (>5 to ≤17 years) (n = 22) received each standardized formulation (liquid and
capsule) on separate occasions in a randomized, crossover fashion. The second dose was
administered between 24 hours and 10 days following the initial dose. Following all HU
dosing, blood PK samples were collected predose and then at 10, 15, 30, 45, and 60 minutes,
and 1.5, 2, 4, 6, and 8 hours postdose in both arms. To ensure balanced enrollment, arm 1
was subdivided into ages 2–3 years and 4–5 years, and arm 2 was divided into ages 6–11
years and 12–17 years.
Investigational Products

Author Manuscript

Hydroxyurea USP was purchased from a commercial pharmaceutical company and
reconstituted with a commercially available cherry syrup diluent to a final concentration of
100 mg/mL at each site’s investigational pharmacy. Droxia® capsules (200 mg) were
purchased and supplied to study sites without modification or disturbance of the
commercially obtained bottles. Capsules were administered whole and were not opened.
Children received HU at a dose of either 20 mg/kg if they were HU naive or their normal
daily dosage (rounded to the nearest 200 mg and no greater than 30 mg/kg) for children
currently prescribed HU therapy.

Bioanalytical Methods
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Whole blood (1 mL) was collected into heparinized tubes, inverted a minimum of 8 to 10
times, placed immediately on ice, and centrifuged at 750g for 10 minutes at 4°C. Plasma
was then stored at −70°C until shipped to Children’s Mercy Hospital, where it was analyzed.
PK samples were analyzed using a validated gas chromatography-mass spectrometry (GC13
MS) technique that was linear from 0.1 to 100 μg/mL of HU. The intra- and interassay
coefficients of variation (CV) were consistently <10% across concentrations spanning the
14
range of linearity.
Bioavailability and a Noncompartmental PK Method
A noncompartmental PK analysis was performed using WinNonlin software (Certera,
Princeton, New Jersey). All PK parameters were expressed with descriptive statistics of
arithmetic mean, standard deviation (SD), and coefficient of variation (CV%).
15
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The assessment of bioavailability followed FDA guidelines. The geometric least-squares
(LS) means of the maximum observed plasma concentration (Cmax), the area under the
concentration-vs-time curve calculated using the log-linear trapezoidal method from time 0
to the last quantifiable concentration (AUClast), and the area under the concentration-vs-time
curve calculated using the log-linear trapezoidal method from time 0 extrapolated to time
infinity (AUC∞) were generated using WinNonlin. The ratio of these parameters for liquid:
capsule and their 90% confidence limits were also obtained using WinNonlin. The paired ttest used to compare Cmax, AUClast, AUC∞, and time to maximum plasma concentration
(Tmax) and the assessment of mean (SD; range) was calculated using Microsoft Excel 2007.
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A 1-compartment model with absorption described by a series of transit compartments was
fitted to the concentration-time profiles of HU using the following equations:
(1)

where A is the amount of HU in the central compartment, CL is the systemic clearance, V is
the volume of distribution, F is the fraction of the dose absorbed, plasma concentrations (Cp)
= A/V, and Input(t) denotes the input rate of HU into the central compartment:

(2)

Author Manuscript

where t is the time since the first dose, Dosek denotes the dose given at kth visit (occasion) at
time TODk, and I(x,y) is the individual input function defined as:
(3)

Author Manuscript

where ktr is the first-order transit rate constant equal to (N+1)/MTT; MTT (mean transit
time) corresponds to the average time spent by a molecule traveling from the dirst to the
central compartment (average absorption time), and N is number of transit compartments.
The actual parameters generated were CL/F and V/F due to uncertain bioavailability.
Equations 1–3 allow for joint estimation of the number of compartments and MTT.
Interindividual variability (IIV) represented by η and interoccasion variability (IOV)
represented by κ were modeled assuming the log normal distribution. Model fitting and
covariate analysis were performed using NONMEM software (version 7.2.0, Icon
Development Solutions, Ellicott City, Maryland) as described in the supplemental materials.
Allometric Scaling
The effect of body size on the volume and clearance parameters was predicated on
allometric principles with theoretical exponents as follows:
(4)

Author Manuscript

(5)

where Vi and CLi denote the individual values of volume and clearance; θV and θCL are the
population (typical) estimates of volume and clearance, BWi,k is the individual body weight
on the kth occasion (visit), and 70 is the body weight (kg) of a standard adult. This approach
facilitated the comparison of PK parameters with adult data.
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Relationships between patient-specidic covariates (such as age, sex, height, alkaline
phosphate, alanine transaminase, aspartate transaminase, direct bilirubin, blood urine
nitrogen, creatinine, glucose, potassium, sodium, and sickle cell genotype) and the empirical
Bayes estimates of η and κ for each PK parameter were sought by plotting individual
estimates of η and κ against tested covariates to identify their indluence. Potential
relationships were subsequently evaluated using nonlinear mixed-effect modeling with the
stepwise forward inclusion (P < .05) and backward elimination (P < .005) method. Further
details regarding covariate assessment are provided in the supplemental materials.

Results
Author Manuscript

In total, 39 participants enrolled. In arm 1, 94% (n = 16/ 17) of young children (n = 6, aged
2–3 years; n = 10, aged 4–5 years) received study drug. All 16 children completed the study
and are included in the PK and safety analyses. In arm 2, 25 children were enrolled, and
92% (n = 23; 12 aged 6–11 years, 11 aged 12–17 years) received study drug and are
included in the PK and safety analyses. For the bioavailability analysis of participants in arm
2, 96% of children (n = 22) completed both PK visits, with 48% (n = 11) receiving capsule
formulation first. One participant voluntarily withdrew from the second PK analysis due to
loss of intravenous access. The PK samples obtained with the study drug (liquid
formulation) during this child’s first PK visit were analyzed in the PK and safety analysis.
Table 1 summarizes demographic, baseline laboratory parameters, and HU dose by study
arm and participant age.
Bioavailability

Author Manuscript

The PK of liquid (n = 22) and capsule (n = 22) formulations were similar (Table 2). Figure 1
shows HU concentration-vs-time profiles in 4 representative children who received both
liquid and capsule formulations. Both formulations were rapidly absorbed with a mean (SD)
Tmax of 0.86 (0.53) hours and resulted in a Cmax of 33.8 (8.3) μg/mL. The half-life was 2.3
(0.5) hours, and clearance averaged 0.20 (0.03) L/(h · kg). Comparing the capsule and liquid
formulations using the geometric least-squares mean ratios of the 3 bioequivalence metrics
(Cmax, AUClast, and AUC∞), the formulations were nearly 100% identical and well within
the 90% confidence limits (Table 3).
Noncompartmental Analysis

Author Manuscript

Noncompartmental analyses were performed in children (≥2 to ≤5 years) in arm 1 and in the
single participant in arm 2 who withdrew prior to completion of the second PK visit as well
as in older children (>5 to ≤17 years) in arm 2. In young children, following a mean (SD)
dose of 22.7 (3.0) mg/kg of HU, absorption was rapid with a mean (SD) Tmax of 0.57 (0.34)
hours. The decline phase after a Cmax of 37.4 (9.3) μg /mL was well captured, and the
average half-life was 1.96 (0.18) hours. The mean residence time (MRT) was small,
averaging 2.6 (0.3) hours. The apparent clearance was consistent among these subjects,
averaging 0.234 (0.028) L/(h ·kg). In older children (arm 2), HU was rapidly absorbed with a
Tmax of 0.86 (0.53) hours, mean Cmax was 33.8 (8.3) μg/mL, and the mean half-life was 2.31
(0.47) hours. The MRT was also small, averaging 2.8 (0.4) hours.
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Table 4 provides a summary of existing studies assessing the PK properties of HU in patients
with SCA. Children from the bioavailability analysis (arm 2) and those from the single-dose
(arm 1) analysis are presented separately.
Population Pharmacokinetic Modeling
Individual HU concentration-time profiles are shown in Figure S1. The available data
consisted of 682 plasma concentrations with 62 measurements (60 predose) below the level
of quantification. Five predose concentrations were above the limit of quantification and
were treated as outliers.

Author Manuscript

A 1-compartment model with first-order absorption was initially used to describe the data.
However, delayed absorption in several children required a more flexible model. Therefore,
a model with a series of transit compartments describing absorption and a 1-compartment
model describing disposition were designed that successfully characterized the trend and
variability in the data. Figure S2 demonstrates the goodness-of-fit plots of the final model.
The individual and population predictions vs observed concentrations are symmetrically
distributed around the line of identity. The visual predictive plots stratified by formulation
are presented in Figure S3. Individual predicted concentration-vs-time profiles were very
close to the experimental data (Figures S4a–d).

Author Manuscript

All PK parameters, intersubject, interoccasion, and residual error variances had CVs smaller
than 55% (Table S3). The intraindividual variability for the number of transit compartments
(N) tended to 0 during the model-building process and was fixed to 0. The intraindividual
variability for MTT was not significantly different from 0 as tested by the decrease in the
NONMEM objective function and was also fixed to 0. The IOV was tested only for MTT, as
the absorption rate was the most likely reason for the PK difference seen for 2 consecutive
visits of the participants.
The apparent volume of distribution equaled 45.4 L, and the apparent systemic clearance
was 11.9 L/h for a theoretical patient of 70 kg. Allometric scaling accounted for the weight
differences observed in disposition parameters (CL/F, V/F) with the standard exponent of
0.75 for clearance and 1 for distribution volume. The IIV for CL/F and V/F were small (CV
% less than 10%). The mean absorption time was almost 2-fold greater for capsules (0.318
hours) than for liquid (0.181 hours), with high IOV of 63%. The graphical presentation of
weight, sex, and formulation effects on PK parameters is provided in Figure 2.

Author Manuscript

Age, sex, height, and laboratory variables (Table 1) were not significant covariates in this
study (data not shown).
Safety Results
All participants tolerated the single dose of hydroxyurea and all study-related procedures
without apparent adverse events attributed to them. AE data are provided in Table S4.
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Discussion
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Hydroxyurea is a crucial therapy for children with SCA. Its off-label designation for
children concerns parents and has been identified as a significant barrier to widespread
20
acceptance. In addition, only having access to capsule formulations can impede pediatric
21
use both because toddlers and many older children lack the ability to swallow capsules and
because clinicians have difficulties in adapting fixed capsule formulations to dosing in small
children. This trial specifically addresses pharmacologic limitations that had been identified
by the FDA as necessary for regulatory approval for pediatric use and liquid formulation:
comparative PK data on the bioavailability of liquid vs capsule formulations and the PK
profile of HU in children across cohorts of different ages. Many drugs experience agerelated differences in absorption, distribution, metabolism, and excretion that have
22
15
therapeutic implications. Based on FDA guidelines, our data conclusively address both
regulatory limitations. A liquid preparation of HU (100 mg/mL) diluted in cherry syrup is
bioequivalent to Droxia® (200 mg) capsules. Furthermore, toddlers who received a liquid
formulation of HU had similar PK profiles to older children who received either liquid or
capsule formulations. Independent of formulation or age between 2 and 18 years, toddlers
and children with SCA had rapid absorption that translated to a predictable disposition of the
medication.

Author Manuscript
Author Manuscript

Currently, there are limited data evaluating the PK of HU in children. Previous studies have
23
shown that HU has excellent oral bioavailability with rapid but variable absorption and
16 17 24
rapid elimination with half-life of approximately 2 hours. , , In this prospective, openlabel trial, we investigated the PK in children following ingestion of liquid and/or capsule
formulations of HU followed by early and frequent blood sampling. Both formulations had
rapid absorption (Tmax 0.86 hours) with a peak concentration of 33.8 μg/mL. Interpersonal
variation was observed in the absorption time of HU in both younger and older children.
17
This variation has been reported and may be due to variations in transmembrane
25
transporters. Between liquid and capsule formulations, the largest difference in the PK
profiles was a trend toward a shorter time to peak concentration following ingestion of the
liquid compared with the capsule, but that difference did not reach statistical significance
(0.74 versus 0.97 hours, P = 0.14; Table 2). Pediatric PK data for HU are limited to 3
studies: observations from the internal pilot study (consisting of the first 22 participants) of
16
the NIH-sponsored BABY HUG trial, a study of children with SCA administered an oral
18
17
tablet formulation, and children receiving a first-dose of HU via a liquid suspension
16
(Table 4). In the NIH-sponsored BABY HUG trial, as part of an internal pilot study, 22
very young children (mean age 14.7 months) underwent PK sampling following their first
dose of liquid HU. PK samples were collected predose and then 1, 2, and 4 hours following
ingestion. The Cmax and AUC∞ (19.8 μg/mL and 68.8 μg · h/mL) were lower than our
18
results and those of subsequently published pediatric studies. At the time, the authors felt
this was suggestive that the PK profile of liquid HU in very young children may be different
18
from that in adults. Subsequently, de Montalembert et al reported PK profiles in 11
children at a mean (SD) age of 10.2 (5.5) years who ingested a coated breakable HU tablet.
The Cmax in that population was 24.5 μg/mL, with an AUC∞ of 115.8 μg · h/mL. Finally,
17
Ware et al performed PK testing following a first dose of HU (liquid, n = 77; capsule, n =

J Clin Pharmacol. Author manuscript; available in PMC 2017 March 01.

Estepp et al.

Page 9

Author Manuscript

10) at mean (SD) age of 9.6 (4.8) years. Children given the liquid formulation had a lower
peak concentration (25.4 μg/mL) and shorter half-life (1.64 hours) but a similar AUC∞ (91.9
μg · hr/mL) when compared with children given a capsule (31.9 μg/mL, 2.17 hours, and
101.0 μg · h/mL).

Author Manuscript

In contrast to previous studies in children, we pursued a protocol of early and aggressive
monitoring of plasma concentrations. Liquid and capsule formulations resulted in similar
AUC∞, similar Cmax, and similar half-life (Table 2). In our participants, 21.0% (8/39) of
children receiving a liquid formulation reached a peak drug concentration between 30 and
60 minutes. The first scheduled blood sampling in the BABY HUG trial’s internal pilot
occurred at 1 hour following HU ingestion. This time point was likely after the peak
concentration had been reached and during the precipitous phase of drug elimination, which
may have potentially overestimated the Tmax and underestimated the Cmax and AUC∞. All
11 children reported by de Montalembert et al reached Tmax at the first blood sample draw,
18
which was 45 minutes following dosing. This timing also suggests that participants may
have reached Tmax prior to sampling. In contrast, the 77 children reported by Ware et al
included early blood sampling (15 and 30 minutes postdose). However, samples were not
17
obtained between 30 minutes and 1 hour, which is the time frame that 1 in 5 children given
the liquid reached peak drug concentrations in our cohort. That timing may have led to a
longer calculated Tmax and underestimated Cmax and AUC∞.

Author Manuscript

We report that a population PK model was successfully developed to describe the time
course of HU concentrations after oral administration in children with SCA. This model
adequately captured the variability in absorption and disposition of HU. Body weight was
found to influence both the apparent clearance and volume of distribution and was the main
factor that varied with age. Measures of medication exposures (AUC- or CL/F-related) were
not altered by formulation; therefore, dosing adjustments are not required for transitioning
from one formulation to another. Additionally, this model offers confidence, with respect to
dosing and PK, that current standard-practice dosing schemes that adjust for weight result in
similar drug exposures over time.
One limitation of this study is that we did not ascertain if differences exist in PK parameters
following a single dosage and during steady-state sampling with chronic daily
administration. Although this was initially planned as an aim of this study, it was unable to
be completed due to difficulty in recruiting participants. Also, this study did not assess the
PK of HU in infants or in children less than 2 years of age.

Author Manuscript

In summary, a solution of HU in cherry syrup compared with Droxia® capsules meets FDA
15
requirements of bioequivalence in children. Our results demonstrate that (1) exposure to
HU is not significantly altered based on liquid or capsule formulation, making dosing
adjustments for differences in either drug formulation or age unnecessary, and (2) standard
weight-based dosing schemes of HU provide consistent drug exposure. These data support
the use of liquid HU in children who are unable to swallow capsules and in those whose low
weight precludes the use of fixed capsule formulations. These findings should encourage the
use of HU across the spectrum of both age and weight in children with SCA, and they
should facilitate the expanded use of HU as recently recommended in the NHLBI guidelines
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for care of children with SCA. Importantly, satisfying FDA regulatory requirements for
pediatric approval of HU could address additional barriers to use.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representative hydroxyurea concentration (μg/mL) per time (hour) profiles in 4 selected
children who were given both liquid (–○–) and capsule (–●–) formulations.
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Figure 2.

Relationship of body-weight-normalized apparent clearances (CL/F/BW and CL/F/
BW^0.75) vs age for all children. Closed symbols (●) denote males, and open symbols (○)
denote females.
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Table 1

Author Manuscript

Demographic, Baseline Laboratory Parameters, and Hydroxyurea Dosage by Study Arm
Arm 1, n = 16

Category; Mean (SD)

Arm 2, n = 23

2–3 Years

4–5 Years

6–11 Years

12–17 Years

n=6

n = 10

n = 12

n = 11

Demographics
Age, years

3.1 (0.5)

4.8 (0.5)

9.0 (1.4)

15.1 (2.0)

Height, cm

96.3 (4.8)

109.5 (5.2)

132.4 (7.0)

162.5 (9.8)

Weight, kg

14.8 (1.4)

18.2 (2.2)

28.2 (4.9)

53.3 (13.9)

Baseline laboratory parameters
WBC, 103/L

11.9 (3.2)

10.6 (4.0)

9.4 (3.7)

6.9 (2.3)

Hb, g/L

87.7 (15.8)

86.9 (10.2)

87.8 (9.7)

93.6 (19.0)

90.4 (8.6)

93.9 (12.5)

91.9 (8.9)

95.2 (14.0)

432 (172)

402 (167)

397 (116)

372 (208)

140.0 (1.9)

138.0 (1.8)

139.6 (2.3)

141.8 (3.1)

Potassium, mmol/L

4.5 (0.6)

4.3 (0.2)

4.3 (0.3)

4.2 (0.5)

BUN, mmol/L

2.6 (1.3)

3.1 (0.9)

3.2 (1.0)

2.6 (0.9)

MCV, fL

Author Manuscript

Platelets,

103/L

Sodium, mmol/L

Creatinine, μmol/L

23.8 (11.4)

28.6 (5.1)

36.0 (7.8)

43.3 (10.9)

ALP, U/L

178.7 (30.5)

153.3 (25.1)

167.8 (65.0)

135.4 (56.1)

AST, U/L

47.2 (11.8)

43.2 (13.4)

51.1 (17.2)

49.7 (20.1)

BiliT, μmol/L

33.1 (12.7)

31.8 (14.4)

45.0 (20.7)

34.5 (16.2)

Liquid

23.6 (3.0)

24.1 (4.2)

21.0 (4.5)

24.4 (4.9)

Capsule

N/A

N/A

21.3 (4.6)

24.5 (5.1)

Hydroxyurea dose, mg/kg

Author Manuscript

SD indicates standard deviation; WBC, white blood cell; Hb, hemoglobin; MCV, mean corpuscular volume; BUN, blood urea nitrogen; ALP,
alkaline phosphatase; AST, aspartate aminotransferase; BiliT, total bilirubin; N/A, not applicable.

Author Manuscript
J Clin Pharmacol. Author manuscript; available in PMC 2017 March 01.

Estepp et al.

Page 16

Table 2
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Pharmacokinetic Parameters in Children in Arm 2 for Capsule and Liquid Formulations of Hydroxyurea
Parameters, Mean (SD)
Cmax (μg/mL)

Both
n = 44

Capsule
n = 22

Liquid
n = 22

33.8 (8.3)

33.6 (8.2)

34.0 (8.7)

Tmax (hour)

0.86 (0.53)

0.97 (0.52)

0.74 (0.5)

AUClast (μg · h/mL)

101.7 (24.7)

103.0 (25.4)

100.3 (24.6)

AUC∞ (μg ·h/mL) −1)

114.1 (29.4)

116.3 (30.0)

111.9 (29.4)

λz (hour

0.31 (0.05)

0.31 (0.05)

0.31 (0.05)

t½(hours)

2.3 (0.5)

2.3 (0.5)

2.3 (0.5)

MRT (hours)

2.8 (0.4)

2.9 (0.4)

2.8 (0.4)

0.20 (0.03)

0.20 (0.03)

0.21 (0.04)

CL/F/BW (L/[hr · kg])

Author Manuscript

Cmax, maximum observed plasma concentration; Tmax, time to maximum plasma concentration; AUClast, area under the concentration-vs-time
curve calculated using the log-linear trapezoidal method from time 0 to the last quantifiable concentration; AUC∞, area under the concentrationvs-time curve calculated using the log-linear trapezoidal method from time 0 extrapolated to time ∞; λz, terminal elimination slope constant; t½,
terminal elimination half-life calculated as ln2/λz; MRT, mean residence time; CL/F/ BW, clearance normalized for body weight. Parameters for
liquid and capsule formulations compared with a paired 2-tailed t-test, and none were significantly different.
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113.3

AUC∞ (μg ·h/mL)

110.1

98.6

33.1

Liquid

97.2

98.3

102.4

Ratio (%)

Abbreviations defined in Table 2; LS indicates least-squares.

100.3·

32.3

Capsule

AUClast (μg ·h/mL)

Cmax (μg/mL)

Parameters (Units)

Geometric LS Mean

93.4

94.5

91.8

Lower

101.1

102.3

114.2

Upper

90% Confidence Limits
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Assessment of Hydroxyurea Bioavailability via FDA Guidelines
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18

2005

2006

2006

2011

7

15

11

87

22

22

22

17

N

~40

30.1

10.2 (5.5)

9.6 (4.8)

1.2 (NR)

12.0 (3.6)

12.0 (3.6)

4.5 (1.7)

Age, Years

15

20.9

21.9

20

20

22.6 (4.9)

21.7 (6.4)

22.7 (3.0)

Dose, mg/kg

capsule

both

tablets

liquid

liquid

capsule

liquid

liquid

Formulation

28.3 (11.0)

26.5

24.5

26.1 (6.8)

19.8 (5.8)

33.6 (8.2)

34.0 (8.7)

37.4 (9.3)

Cmax,μg/mL

82.5 (15.5)

128.4

115.8

93.0 (23.4)

68.8 (11.5)

116.3 (30.0)

111.9 (29.4)

104.5 (18.8)

AUC∞,μg · h/mL

Abbreviations are defined in Table 2; NR indicates not reported. Data presented are mean (standard deviation).

Yan et al

19

de Montalembert et al

Adults

de Montalembert et al

Ware et al

17

Rogers et al

18

–

Arm 2

2005

–

Arm 2

16

–

Arm 1

Children

Year

Study

0.5

0.86

0.75

0.82 (0.47)

NR

0.97 (0.52)

0.74 (0.52)

0.57 (0.34)

Tmax, hr

Author Manuscript

Summary of Published Pharmacokinetic Parameters of Hydroxyurea

3.14

6.3

6.3

1.70 (0.53)

2.36 (0.99)

2.31 (0.47)

2.3 (0.5)

1.96 (0.18)

t½, hr

0.194

0.154

0.127

0.24 (0.09)

NR

0.20 (0.03)

0.205 (0.035)

0.234 (0.028)

CL/F/BW, L/(h · kg)
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